Yipinhong (300723.SZ) subsidiary's innovative drug APH03571 tablets approved for clinical trials.

Zhijing Finance APP News, OnePiece (300723.SZ) announced that recently, the drug clinical trial application for the innovative drug APH03571 tablets developed independently by the company's wholly-owned subsidiary, Guangzhou OnePiece Pharmaceutical Co., Ltd., has been approved by the National Medical Products Administration, and has received the "Drug Clinical Trial Approval Notification", and will conduct clinical trials in the near future. APH03571 is a treatment drug developed by the company for adult patients with relapsed or refractory acute myeloid leukemia carrying FLT3 (full name: FMS-like tyrosine kinase 3) mutations.